Imagine a tiny, life-sustaining organ forming within days of conception, yet its earliest stages have remained shrouded in mystery—until now. UC San Diego researchers have cracked open the secrets of the human placenta's beginnings, potentially revolutionizing our understanding of early pregnancy and fertility treatments. But here's where it gets controversial: could manipulating a single gene hold the key to preventing miscarriages and improving IVF success rates? Let’s dive in.
The placenta is the unsung hero of pregnancy, supplying the developing fetus with essential nutrients, oxygen, and antibodies. This temporary organ starts forming just 6 to 12 days after conception, as the embryo implants into the uterine lining. However, when placental development goes awry, it becomes the second leading cause of early miscarriages, trailing only behind genetic abnormalities incompatible with life. Despite its critical role, studying the placenta’s earliest stages in humans has been ethically and technically challenging—until a groundbreaking study changed the game.
In a recent publication, researchers from the University of California San Diego and their collaborators unveiled a novel approach to unraveling this mystery. By using human pluripotent stem cells—cells capable of transforming into any tissue type—they modeled the formation of the embryo’s outer layer, which eventually develops into the placenta. The team employed a signaling protein called BMP4 (bone morphogenetic protein 4) to mimic the early differentiation of cells in both the embryo and placenta.
Their discovery? A gene named VGLL1 (vestigial-like family member 1) activates remarkably early during placental formation, acting as a master switch. When VGLL1 is active, pluripotent stem cells successfully transform into various placental cell types. But when its activity is reduced, this process grinds to a halt, halting placental development altogether. And this is the part most people miss: VGLL1 doesn’t work alone. It teams up with another protein to regulate placenta-specific genes and directly controls an enzyme called KDM6B, which ‘unlocks’ these genes for activation. Both VGLL1 and KDM6B are highly active in the embryo’s outer layer, particularly in the area where implantation occurs.
While this research is still in its preclinical phase, the implications are staggering. Could targeting VGLL1 or related genes lead to breakthroughs in fertility treatments? Lead researcher Francesca Soncin, assistant professor in the Department of Pathology at UC San Diego School of Medicine, suggests that manipulating these mechanisms might improve embryo transfer success and even enhance embryo viability. But here’s the provocative question: If we can control placental development at such an early stage, are we playing with nature’s design, or are we simply unlocking its potential?
The study, titled ‘VGLL1 contributes to both the transcriptome and epigenome of the developing trophoblast compartment’, was published on November 24, 2025, in PNAS. You can explore the full findings here.
What do you think? Is this a leap forward in reproductive science, or does it raise ethical concerns? Share your thoughts in the comments below. And don’t forget to subscribe to our newsletter to stay updated on the latest breakthroughs from UC San Diego!
